Dongwha Yakpum, Stock Price Down 4.42% at This Hour... 'COVID-19 Treatment Phase 2 Imminent, The Time Has Finally Come'

Dongwha Pharm is trading at 10,800 KRW as of 12:30 PM on the 28th, down 4.42% from the previous day. The trading volume is 554,200 shares, which is 8.19% of the previous day's volume. Dongwha Pharm is known as a manufacturer and seller of pharmaceuticals (such as Gas Hwal Myeong Su and Fusidin).

On May 27, Kim Tae-yeop, a researcher at Hanyang Securities, stated, "DW2008: Covid-19 Phase 2 IND application is imminent. The greatest strength of the DW2008 pipeline is its safety at high doses. Antiviral activity in vitro has already been verified. It is believed that sufficient results can be obtained by increasing the dosage in animal experiments or other methods. Once significance in COVID-19 treatment is demonstrated in animal clinical data, it is expected to proceed directly to Phase 2, replacing the existing Phase 1 data. Now is judged to be the optimal time to buy." He set the target price for Dongwha Pharm at 18,000 KRW.

Over the past five days, individual investors have net purchased 126,486 shares of Dongwha Pharm, while foreigners and institutions have net purchased 2,216 shares and net sold 4,290 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.